Total Payments
$76,950
2024 Payments
$48,960
Companies
12
Transactions
99
Medicare Patients
3,899
Medicare Billing
$284,189
Payment Breakdown by Category
Consulting$25,876 (33.6%)
Research$18,838 (24.5%)
Travel$17,413 (22.6%)
Other$12,119 (15.7%)
Food & Beverage$2,664 (3.5%)
Education$40.69 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $25,876 | 10 | 33.6% |
| Unspecified | $18,838 | 5 | 24.5% |
| Travel and Lodging | $17,413 | 34 | 22.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,103 | 2 | 15.7% |
| Food and Beverage | $2,664 | 42 | 3.5% |
| Education | $40.69 | 5 | 0.1% |
| Entertainment | $15.56 | 1 | 0.0% |
Payments by Type
General
$58,113
94 transactions
Research
$18,838
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $33,227 | 53 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $24,574 | 8 | $0 (2024) |
| Eli Lilly and Company | $5,130 | 1 | $0 (2022) |
| Travere Therapeutics, Inc. | $4,880 | 13 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,080 | 1 | $0 (2022) |
| Novo Nordisk Inc | $2,025 | 2 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,176 | 2 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,040 | 3 | $0 (2022) |
| Janssen Research & Development, LLC | $700.67 | 13 | $0 (2018) |
| Relypsa, Inc. | $84.72 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48,960 | 34 | SANOFI-AVENTIS U.S. LLC ($24,574) |
| 2023 | $3,334 | 8 | Bayer Healthcare Pharmaceuticals Inc. ($3,334) |
| 2022 | $18,019 | 20 | Eli Lilly and Company ($5,130) |
| 2021 | $1,176 | 2 | AstraZeneca Pharmaceuticals LP ($1,176) |
| 2019 | $4,448 | 16 | Bayer HealthCare Pharmaceuticals Inc. ($4,433) |
| 2018 | $700.67 | 13 | Janssen Research & Development, LLC ($700.67) |
| 2017 | $311.86 | 6 | Bayer HealthCare Pharmaceuticals Inc. ($227.14) |
All Payment Transactions
99 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/04/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| 10/29/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $0.37 | General |
| 08/29/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $16.89 | General |
| 08/29/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $11.77 | General |
| 07/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | — | Cash or cash equivalent | $18,626.00 | Research |
| Study: 22267 - Sylvia Rosas • Category: Cardio-renal | ||||||
| 06/28/2024 | SANOFI-AVENTIS U.S. LLC | — | Travel and Lodging | In-kind items and services | $11,071.90 | General |
| 06/28/2024 | SANOFI-AVENTIS U.S. LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,192.00 | General |
| 06/28/2024 | SANOFI-AVENTIS U.S. LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,911.00 | General |
| 06/28/2024 | SANOFI-AVENTIS U.S. LLC | — | Travel and Lodging | In-kind items and services | $594.30 | General |
| 06/28/2024 | SANOFI-AVENTIS U.S. LLC | — | Travel and Lodging | In-kind items and services | $376.44 | General |
| 06/28/2024 | SANOFI-AVENTIS U.S. LLC | — | Food and Beverage | In-kind items and services | $293.08 | General |
| 06/28/2024 | SANOFI-AVENTIS U.S. LLC | — | Travel and Lodging | Cash or cash equivalent | $77.19 | General |
| 06/28/2024 | SANOFI-AVENTIS U.S. LLC | — | Food and Beverage | Cash or cash equivalent | $57.64 | General |
| 06/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Consulting Fee | Cash or cash equivalent | $1,876.00 | General |
| Category: Cardio-renal | ||||||
| 06/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $235.13 | General |
| Category: Cardio-renal | ||||||
| 06/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $70.90 | General |
| Category: Cardio-renal | ||||||
| 06/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $50.40 | General |
| Category: Cardio-renal | ||||||
| 06/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $29.61 | General |
| Category: Cardio-renal | ||||||
| 06/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $10.00 | General |
| Category: Cardio-renal | ||||||
| 05/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $96.83 | General |
| Category: Cardio-renal | ||||||
| 03/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $507.80 | General |
| Category: Cardio-renal | ||||||
| 03/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $102.59 | General |
| Category: Cardio-renal | ||||||
| 03/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $95.48 | General |
| Category: Cardio-renal | ||||||
| 03/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Cardio-renal | ||||||
| 03/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $33.03 | General |
| Category: Cardio-renal | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 22267 - Sylvia Rosas | Bayer Healthcare Pharmaceuticals Inc. | $18,626 | 1 |
| BAY 94 8862 ph 3 conventional in diab nephropathy | Bayer HealthCare Pharmaceuticals Inc. | $211.61 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 222 | 396 | $128,302 | $36,458 |
| 2022 | 26 | 1,379 | 2,208 | $278,405 | $75,331 |
| 2021 | 25 | 1,118 | 1,722 | $285,561 | $81,113 |
| 2020 | 30 | 1,180 | 1,659 | $339,294 | $91,287 |
Total Patients
3,899
Total Services
5,985
Medicare Billing
$284,189
Procedure Codes
86
All Medicare Procedures & Services
86 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 75 | 122 | $40,870 | $14,140 | 34.6% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 55 | 140 | $38,640 | $8,441 | 21.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 45 | 47 | $27,307 | $6,901 | 25.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 28 | 53 | $11,183 | $3,550 | 31.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 34 | $10,302 | $3,426 | 33.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 91 | 168 | $73,920 | $25,168 | 34.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 56 | 60 | $34,860 | $9,902 | 28.4% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 46 | 128 | $35,328 | $7,733 | 21.9% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2022 | 16 | 70 | $19,320 | $5,232 | 27.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 49 | 82 | $17,302 | $4,922 | 28.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 24 | 45 | $13,635 | $3,936 | 28.9% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2022 | 64 | 91 | $16,107 | $3,708 | 23.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $11,033 | $3,093 | 28.0% |
| 82306 | Vitamin d-3 level | Office | 2022 | 63 | 91 | $11,375 | $2,659 | 23.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 12 | 15 | $4,500 | $1,480 | 32.9% |
| 80051 | Blood test panel for electrolytes (sodium potassium, chloride, carbon dioxide) | Office | 2022 | 73 | 124 | $3,720 | $854.20 | 23.0% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 58 | 81 | $3,402 | $776.15 | 22.8% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2022 | 77 | 115 | $3,220 | $734.52 | 22.8% |
| 82565 | Blood creatinine level | Office | 2022 | 75 | 126 | $3,402 | $638.17 | 18.8% |
| 82310 | Calcium level, total | Office | 2022 | 77 | 117 | $2,808 | $596.02 | 21.2% |
| 82043 | Urine microalbumin (protein) level | Office | 2022 | 70 | 104 | $6,656 | $592.08 | 8.9% |
| 82040 | Albumin (protein) level | Office | 2022 | 78 | 116 | $3,132 | $566.60 | 18.1% |
| 84100 | Phosphate level | Office | 2022 | 76 | 114 | $2,280 | $533.70 | 23.4% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2022 | 70 | 104 | $2,808 | $529.53 | 18.9% |
| 84520 | Urea nitrogen level to assess kidney function, quantitative | Office | 2022 | 73 | 122 | $2,074 | $475.12 | 22.9% |
About Dr. Sylvia Rosas, MD
Dr. Sylvia Rosas, MD is a Nephrology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568497600.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sylvia Rosas, MD has received a total of $76,950 in payments from pharmaceutical and medical device companies, with $48,960 received in 2024. These payments were reported across 99 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($25,876).
As a Medicare-enrolled provider, Rosas has provided services to 3,899 Medicare beneficiaries, totaling 5,985 services with total Medicare billing of $284,189. Data is available for 4 years (2020–2023), covering 86 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Other Specialties Nephrology
- Location Boston, MA
- Active Since 07/11/2006
- Last Updated 01/03/2019
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1568497600
Products in Payments
- Kerendia (Drug) $26,289
- Non-Covered (Drug) $4,433
- FARXIGA (Drug) $1,167
- JARDIANCE (Drug) $1,040
- Non-Covered $227.14
- Veltassa (Drug) $84.72
- t:slim X2 Insulin Pump with Control-IQ (Device) $18.08
- LOKELMA (Drug) $9.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Boston
David Friedman, M.d, M.D
Nephrology — Payments: $20.3M
Nephrology $20.3M
Martin Pollak, Md, MD
Nephrology — Payments: $20.3M
Nephrology $20.3M
Dr. Dennis Ausiello, Md, MD
Nephrology — Payments: $4.4M
Nephrology $4.4M
Dr. Ajay Singh, Md, MD
Nephrology — Payments: $1.2M
Nephrology $1.2M
Dr. Leslie Fang, Md, MD
Nephrology — Payments: $795,357
Nephrology $795,357
Dr. Jean Francis, M.d, M.D
Nephrology — Payments: $217,413
Nephrology $217,413